US allocates $2 million for psychedelic research into Substance Use Disorder
The US National Institute on Drug Abuse (NIDA) has earmarked $2 million in funding for psychedelic treatment research into Substance Use Disorder (SUD).
NIDA will commit the funds to three to five awards with a budget of $2 million per year. The NIDA Notice of Funding Opportunity has been made available under the UG3/UH3 Phased Innovation Awards Cooperative Agreement.
The funding will go toward research that explores the development of classic psychedelics such as psilocybin and LSD, empathogens like MDMA, dissociatives such as ketamine, and other hallucinogens for the treatment of SUD.READ MORE